Finch Therapeutics Group (FNCH) Competitors $12.03 -0.22 (-1.80%) As of 10:03 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. EXOZ, OVID, WHWK, CNTX, CVM, IGMS, UNCY, INCR, ASRT, and PMVPShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include eXoZymes (EXOZ), Ovid Therapeutics (OVID), Whitehawk Therapeutics (WHWK), Context Therapeutics (CNTX), CEL-SCI (CVM), IGM Biosciences (IGMS), Unicycive Therapeutics (UNCY), InterCure (INCR), Assertio (ASRT), and PMV Pharmaceuticals (PMVP). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors eXoZymes Ovid Therapeutics Whitehawk Therapeutics Context Therapeutics CEL-SCI IGM Biosciences Unicycive Therapeutics InterCure Assertio PMV Pharmaceuticals eXoZymes (NASDAQ:EXOZ) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership. Does the media prefer EXOZ or FNCH? In the previous week, eXoZymes had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for eXoZymes and 1 mentions for Finch Therapeutics Group. eXoZymes' average media sentiment score of 1.28 beat Finch Therapeutics Group's score of 0.00 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Finch Therapeutics Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, EXOZ or FNCH? eXoZymes has higher revenue and earnings than Finch Therapeutics Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymes$70K1,162.61-$5.86MN/AN/AFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.36 Is EXOZ or FNCH more profitable? Finch Therapeutics Group's return on equity of -69.14% beat eXoZymes' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A -134.50% -81.63% Finch Therapeutics Group N/A -69.14%-26.92% Do institutionals & insiders hold more shares of EXOZ or FNCH? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryeXoZymes beats Finch Therapeutics Group on 5 of the 8 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.32M$282.89M$5.75B$9.84BDividend YieldN/AN/A3.95%4.02%P/E Ratio-1.36N/A30.7626.60Price / SalesN/A553.67459.33120.41Price / CashN/A22.4437.7659.36Price / Book0.8410.2810.036.70Net Income-$74.75M-$115.81M$3.27B$265.68M7 Day Performance-10.76%2.37%3.36%3.42%1 Month Performance-3.76%-4.81%4.58%1.09%1 Year Performance-6.02%-12.85%44.38%23.94% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group0.3104 of 5 stars$12.03-1.8%N/A+0.4%$19.32MN/A-1.36190EXOZeXoZymesN/A$9.70+4.1%N/AN/A$81.31M$70K0.0029OVIDOvid Therapeutics4.183 of 5 stars$1.22+7.0%$3.10+154.1%-1.6%$81.07M$570K-2.3060Analyst RevisionWHWKWhitehawk TherapeuticsN/A$1.81+6.5%N/AN/A$80.12M$21.60M-30.1740CNTXContext Therapeutics3.5547 of 5 stars$0.86-1.5%$5.25+510.8%-65.6%$78.30MN/A-2.397News CoverageGap UpCVMCEL-SCI0.6557 of 5 stars$11.30+7.0%N/A-61.2%$77.77MN/A-23.5443News CoverageGap DownIGMSIGM Biosciences4.6012 of 5 stars$1.27flat$5.50+333.1%N/A$76.57M$145.05M-1.41190Positive NewsUNCYUnicycive Therapeutics2.6942 of 5 stars$4.25-0.9%$60.00+1,311.8%+19.8%$75.77MN/A-1.039News CoverageINCRInterCure0.8118 of 5 stars$1.64-1.5%N/A-23.5%$75.65M$238.85M0.00350Positive NewsASRTAssertio2.1908 of 5 stars$0.78-0.6%$2.38+204.2%-36.4%$75.61M$124.96M-1.7420Analyst DowngradePMVPPMV Pharmaceuticals3.172 of 5 stars$1.44+1.4%$5.50+281.9%-10.1%$75.25MN/A-0.9250Positive NewsHigh Trading Volume Related Companies and Tools Related Companies EXOZ Alternatives OVID Alternatives WHWK Alternatives CNTX Alternatives CVM Alternatives IGMS Alternatives UNCY Alternatives INCR Alternatives ASRT Alternatives PMVP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access